Table I.

Comparative analysis of HIV-1 association with rhTRIM5α

Viral envelopeCell typeTreatmentTotal TRIM associationTRIM association




S15+ (unfused)
S15 (fused)
   % % % 
VSV-G rhTRIM-HA HeLa MG132 35.1 (Fig. 1 B) ND ND 
None rhTRIM-HA HeLa MG132 2.5 (Fig. 1 B) ND ND 
HIV rhTRIM-HA HeLa MG132 12.4 (Fig. 1 C) ND ND 
HIV rhTRIM-HA HeLa MG132 + AMD3100 7.3 (Fig. 1 C) ND ND 
VSV-G rhTRIM-HA HeLa BafA 1.7a 1.5 (Fig. 1 D) 5.1 (Fig. 1 D) 
VSV-G rhTRIM-HA HeLa MG132 28.6a 5.0 (Fig. 1 D) 44.7 (Fig. 1 D) 
VSV-G rhTRIM-HA CRFK No drug 17.8a 4.7 (Fig. 3 B) 32.1 (Fig. 3 B) 
VSV-G rhΔpatch-HA CRFK No drug 5.1a 3.2 (Fig. 3 B) 7.5 (Fig. 3 B) 
VSV-G rhTRIM-HA CRFK MG132 13.7a 5.4 (Fig. 3 C) 26.5 (Fig. 3 C) 
VSV-G rhΔpatch-HA CRFK MG132 6.9a 6.2 (Fig. 3 C) 7.9 (Fig. 3 C) 
Viral envelopeCell typeTreatmentTotal TRIM associationTRIM association




S15+ (unfused)
S15 (fused)
   % % % 
VSV-G rhTRIM-HA HeLa MG132 35.1 (Fig. 1 B) ND ND 
None rhTRIM-HA HeLa MG132 2.5 (Fig. 1 B) ND ND 
HIV rhTRIM-HA HeLa MG132 12.4 (Fig. 1 C) ND ND 
HIV rhTRIM-HA HeLa MG132 + AMD3100 7.3 (Fig. 1 C) ND ND 
VSV-G rhTRIM-HA HeLa BafA 1.7a 1.5 (Fig. 1 D) 5.1 (Fig. 1 D) 
VSV-G rhTRIM-HA HeLa MG132 28.6a 5.0 (Fig. 1 D) 44.7 (Fig. 1 D) 
VSV-G rhTRIM-HA CRFK No drug 17.8a 4.7 (Fig. 3 B) 32.1 (Fig. 3 B) 
VSV-G rhΔpatch-HA CRFK No drug 5.1a 3.2 (Fig. 3 B) 7.5 (Fig. 3 B) 
VSV-G rhTRIM-HA CRFK MG132 13.7a 5.4 (Fig. 3 C) 26.5 (Fig. 3 C) 
VSV-G rhΔpatch-HA CRFK MG132 6.9a 6.2 (Fig. 3 C) 7.9 (Fig. 3 C) 

Data from the experiments averaged in Figs. 1 and Figs.3 were pooled to examine the percentage of all viral particles associating with rhTRIM5α under all conditions examined. The figure from which the pooled data were derived is indicated in parentheses.

a

In the case of experiments examining S15-mCherry, data were pooled to determine the degree of rhTRIM5α associations in both S15+ and S15 populations.

or Create an Account

Close Modal
Close Modal